The downregulation of SRGAP2a, which suppresses podocyte motility by inactivating RhoA and Cdc42, occurs in both DN patients and db/db mice; and increasing podocyte SRGAP2a levels ameliorates both podocyte injury and proteinuria in db/db mice [15]. This evidence concerns the gene SRGAP2 and liver dysplastic nodule.